HBM Holdings (HKSE:02142) Dividend Payout Ratio : 0.00 (As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is HBM Holdings Dividend Payout Ratio?

The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. HBM Holdings's Dividend Payout Ratio for the months ended in Jun. 2024 was 0.00.

The historical rank and industry rank for HBM Holdings's Dividend Payout Ratio or its related term are showing as below:

HKSE:02142's Dividend Payout Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.48
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2025-01-19), the Dividend Yield % of HBM Holdings is 0.00%.

HBM Holdings's Dividends per Share for the months ended in Jun. 2024 was HK$0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.

HBM Holdings Dividend Payout Ratio Historical Data

The historical data trend for HBM Holdings's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HBM Holdings Dividend Payout Ratio Chart

HBM Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dividend Payout Ratio

Get a 7-Day Free Trial

HBM Holdings Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Dividend Payout Ratio	Get a 7-Day Free Trial							-	-	-	-	-

Competitive Comparison of HBM Holdings's Dividend Payout Ratio

For the Biotechnology subindustry, HBM Holdings's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HBM Holdings's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HBM Holdings's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where HBM Holdings's Dividend Payout Ratio falls into.

HBM Holdings Dividend Payout Ratio Calculation

HBM Holdings's Dividend Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Dec. 2023 )	/	EPS without NRI (A: Dec. 2023 )
	=	0	/	0.242
	=	0.00

HBM Holdings's Dividend Payout Ratio for the quarter that ended in Jun. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Jun. 2024 )	/	EPS without NRI (Q: Jun. 2024 )
	=	0	/	0.015
	=	0.00

HBM Holdings (HKSE:02142) Dividend Payout Ratio Explanation

In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

HBM Holdings Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of HBM Holdings's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

HBM Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HBM Holdings Ltd (HKSE:02142) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

6XY:Germany

Address

218 Xinghu Street, Suite 202, Building A3, Suzhou Industrial Park, Suzhou, CHN, 215123

Website

https://www.harbourbiomed.com

HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. The majority of the revenue for the firm is generated from the United States.

Executives

Wang Jingsong	2101 Beneficial owner
Gic Private Limited	2102 Investment manager
The Capital Group Companies, Inc.	2201 Interest of corporation controlled by you
Owap Investment Pte Ltd	2101 Beneficial owner
Gic Special Investments Private Limited	2102 Investment manager
Gic (ventures) Pte. Ltd.	2201 Interest of corporation controlled by you
South Dakota Trust Company Llc	2301 Trustee
Jun Lian Zi Ben Guan Li Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you
Pang Kee Chan Hebert
Morgan Stanley Investments (uk)	2201 Interest of corporation controlled by you
Morgan Stanley International Limited	2201 Interest of corporation controlled by you
Morgan Stanley International Holdings Inc.	2201 Interest of corporation controlled by you
Morgan Stanley & Co. International Plc	2105 Underwriter
Advantech Capital Holdings Ltd.
Harbourbio Llc	2101 Beneficial owner

HBM Holdings Headlines

No Headlines